Unexpected link between an antibiotic, pannexin channels and apoptosis

Nature

Volumn 507, Issue 7492, 2014, Pages 329-334

  Poon, Ivan K H ^a,b   Chiu, Yu Hsin ^a   Armstrong, Allison J ^a   Kinchen, Jason M ^a   Juncadella, Ignacio J ^a   Bayliss, Douglas A ^a   Ravichandran, Kodi S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE; CELL MEMBRANE PROTEIN; CIPROFLOXACIN; LEVOFLOXACIN; PANNEXIN 1; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTICS; APOPTOSIS; BACTERIUM; HEALTH RISK; INHIBITION; MEMBRANE; MOLECULAR ANALYSIS; PLASMA;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; APOPTOSIS; ARTICLE; CELL STRUCTURE; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; THYMOCYTE;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; CONNEXINS; DRUG DISCOVERY; FEMALE; FLUOROQUINOLONES; HUMANS; JURKAT CELLS; MALE; MICE; MICE, INBRED C57BL; NAPHTHYRIDINES; NERVE TISSUE PROTEINS; THYMOCYTES;

EID: 84897897084     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13147     Document Type: Article

References (40)

1. Penuela, S., Gehi, R. & Laird, D. W. The biochemistry and function of pannexin channels. Biochim. Biophys. Acta 1828, 15-22 (2013).
2. Sosinsky, G. E. et al. Pannexin channels are not gap junction hemichannels. Channels (Austin) 5, 193-197 (2011).
3. Chen, Y. et al. Purinergic signaling: A fundamental mechanism in neutrophil activation. Sci. Signal. 3, ra45 (2010).
4. Seminario-Vidal, L. et al.Rho signaling regulates pannexin1- mediatedATPrelease from airway epithelia. J. Biol. Chem. 286, 26277-26286 (2011).
5. Se?ror, C. et al. Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J. Exp. Med. 208, 1823-1834 (2011).
6. Billaud, M., Sandilos, J. K. & Isakson, B. E. Pannexin 1 in the regulation of vascular tone. Trends Cardiovasc. Med. 22, 68-72 (2012).
7. Karatas, H. et al. Spreading depression triggers headache by activating neuronal Panx1 channels. Science 339, 1092-1095 (2013).
8. Kim, J. E. & Kang, T. C. The P2X7 receptor-pannexin-1 complex decreases muscarinic acetylcholine receptor-mediated seizure susceptibility in mice. J. Clin. Invest. 121, 2037-2047 (2011).
9. MacVicar, B. A. & Thompson, R. J. Non-junction functions of pannexin-1 channels. Trends Neurosci. 33, 93-102 (2010).
10. Lazarowski, E. R. Vesicular and conductive mechanisms of nucleotide release. Purinergic Signal. 8, 359-373 (2012).
11. Dubyak, G. R. Ion homeostasis, channels, and transporters: An update on cellular mechanisms. Adv. Physiol. Educ. 28, 143-154 (2004).
12. Elliott, M. R. et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461, 282-286 (2009).
13. Chekeni, F. B. et al. Pannexin 1 channels mediate ?find-me? signal release and membrane permeability during apoptosis. Nature 467, 863-867 (2010).
14. Sandilos, J. K. et al. Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-associatedC-terminalautoinhibitory region. J. Biol.Chem.287, 11303-11311 (2012).
15. Qu, Y. et al. Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J. Immunol. 186, 6553-6561 (2011).
16. Liu, H. H. Safety profile of the fluoroquinolones: Focus on levofloxacin. Drug Saf. 33, 353-369 (2010).
17. Stahlmann, R. & Lode, H. Safety considerations of fluoroquinolones in the elderly: An update. Drugs Aging 27, 193-209 (2010).
18. Bruzzone, R., Barbe, M. T., Jakob, N. J. & Monyer, H. Pharmacological properties of homomeric and heteromeric pannexin hemichannels expressed in Xenopus oocytes. J. Neurochem. 92, 1033-1043 (2005).
19. Ma, W., Hui, H., Pelegrin, P. & Surprenant, A. Pharmacological characterization of pannexin-1 currents expressed in mammalian cells. J. Pharmacol. Exp. Ther. 328, 409-418 (2009).
20. Vincent, J. et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J. Antimicrob. Chemother. 39 (suppl. B), 75-80 (1997).
21. Teng, R., Liston, T. E. & Harris, S. C. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J. Antimicrob. Chemother. 37, 955-963 (1996).
22. Wickman, G., Julian, L.& Olson, M. F. Howapoptotic cells aid in the removal of their own cold dead bodies. Cell Death Differ. 19, 735-742 (2012).
23. Moss, D. K., Betin, V. M., Malesinski, S. D. & Lane, J. D. A novel role for microtubules in apoptotic chromatin dynamics and cellular fragmentation. J. Cell Sci. 119, 2362-2374 (2006).
24. Nagata, S., Hanayama, R. & Kawane, K. Autoimmunity and the clearance of dead cells. Cell 140, 619-630 (2010).
25. Bortner, C. D. & Cidlowski, J. A. Caspase independent/dependent regulation of K1, cell shrinkage, and mitochondrial membrane potential during lymphocyte apoptosis. J. Biol. Chem. 274, 21953-21962 (1999).
26. Vanden Berghe, T. et al. Determination of apoptotic and necrotic cell death in vitro and in vivo. Methods 61, 117-129 (2013).
27. Silverman, W., Locovei, S. & Dahl, G. Probenecid, a gout remedy, inhibits pannexin 1 channels. Am. J. Physiol. Cell Physiol. 295, C761-C767 (2008).
28. Cohen, J. J., Duke, R. C., Fadok, V. A.& Sellins, K. S. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 10, 267-293 (1992).
29. Baroja-Mazo, A., Barbera-Cremades, M. & Pelegrin, P. The participation of plasma membrane hemichannels to purinergic signaling. Biochim. Biophys. Acta 1828, 79-93 (2013).
30. Coleman, M. L. et al. Membrane blebbing during apoptosis results from caspasemediated activation of ROCK I. Nature Cell Biol. 3, 339-345 (2001).
31. Sebbagh, M. et al. Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nature Cell Biol. 3, 346-352 (2001).
32. Andriole, V. T. The quinolones: Past, present, and future. Clin. Infect. Dis. 41 (suppl. 2), S113-S119 (2005).
33. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report- 2013/(US Department of Health and Human Services, 2013).
34. Department of Health. UK five year antimicrobial resistance strategy 2013 to 2018. https://www.gov.uk/government/publications/uk-5-year- antimicrobialresistance-strategy-2013-to-2018 (2013).
35. Ahmad, K. Drug company sued over research trial in Nigeria. Lancet 358, 815 (2001).
36. Spellberg, B. et al. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46, 155-164 (2008).
37. Lakso, M. et al. Efficient in vivo manipulation ofmouse genomic sequences at the zygote stage. Proc. Natl Acad. Sci. USA 93, 5860-5865 (1996).
38. Lee, P. P. et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15, 763-774 (2001).
39. Harris, A. L. Connexin channel permeability to cytoplasmic molecules. Prog. Biophys. Mol. Biol. 94, 120-143 (2007).
40. Henry, C. M., Hollville, E. & Martin, S. J. Measuring apoptosis by microscopy and flow cytometry. Methods 61, 90-97 (2013).